PHARMAC documents that matched your search:
The Committee first considered an application from St Ives Medical to list the Orion brand of metronidazole gel 0.5%, 10g on the Pharmaceutical Schedule at it s 22…
Letter to British Medical Journal: Is Celebrex's relative GI safety overstated?
(9 pages, 1176 KB)
Is Celebrex’s relative GI safety is overstated? The editorial by Roger Jones makes important points about the limitations of the meta-analysis by Jon Deeks and colleagues2 for celecoxib. However, we also note that the Deeks meta -analysis does not account for the 12-15-month data for the CLASS study compiled by the FDA3 4 and cited by Peter Juni and colleagues’ critical editorial.
PHARMAC has reached a provisional agreement with Novartis to fund the cancer drug Glivec for a wide group of New Zealanders. PHARMAC is asking for submissions on its funding proposal, which involves a number of products and is subject to the outcome of consultation and final approval by the PHARMAC Board.
Schering proposal involving Mirena, Nova-T, Prognova and Nuvelle
(3 pages, 15 KB)
PHARMAC has signed a provisional agreement with Schering (NZ) dated 19 July 2002 regarding…
Inaugural report of Pharmaceutical Management Agency for the six month period ended 30 June 2001.
PHARMAC’s Objective PHARMAC’s overall objective, as outlined in s.47 (a) the New Zealand Public Health and Disability (NZPHD) Act 2000 is: to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided. This Plan outlines PHARMAC’s objectives for the 2001/02 year.
The theme for 2000-01 is the further development of the supply side tools for the management of expenditure and the development of the Demand Side. These initiatives will continue to support PHARMAC’s goal of optimising the Government’s expenditure on pharmaceutical subsidies.
National Hospital Pharmaceutical Strategy Final Version Pharmaceutical Management Agency 1 February 2002 M16-3-8 #61114 1 Table of Contents Executive Summary 1.0 Introduction 2.0 Current Market Overview 2.1 Current purchasing arrangements 2.2 Range of pharmaceuticals purchased 2.3 Data collection and analysis…